Suppliers and packagers for XYREM

XYREM

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Jazz Pharms	XYREM	sodium oxybate	SOLUTION;ORAL	021196	NDA AUTHORIZED GENERIC	Hikma Pharmaceuticals USA Inc.	0054-9628-57	180 mL in 1 BOTTLE, PLASTIC (0054-9628-57)	2023-01-03
Jazz Pharms	XYREM	sodium oxybate	SOLUTION;ORAL	021196	NDA	Jazz Pharmaceuticals, Inc.	68727-100-01	180 mL in 1 BOTTLE, PLASTIC (68727-100-01)	2002-07-17
Jazz Pharms	XYREM	sodium oxybate	SOLUTION;ORAL	021196	NDA AUTHORIZED GENERIC	Amneal Pharmaceuticals NY LLC	69238-2391-1	180 mL in 1 BOTTLE, PLASTIC (69238-2391-1)	2023-07-03

Xyrem Drug Supply Chain Analysis

Last updated: February 19, 2026

This report analyzes the supply chain for Xyrem (sodium oxybate) and its generic equivalents, focusing on key suppliers, manufacturing processes, regulatory landscapes, and market dynamics. Understanding these elements is critical for evaluating supply reliability, cost structures, and potential risks for pharmaceutical companies and investors.

Who Manufactures Xyrem and Its Generics?

Xyrem, the brand-name drug for sodium oxybate, is manufactured by Jazz Pharmaceuticals. The active pharmaceutical ingredient (API) and finished drug product manufacturing involve specialized processes and stringent regulatory oversight.

Brand-Name Xyrem Manufacturing

• API Manufacturing: The synthesis of sodium oxybate, the API in Xyrem, is a multi-step chemical process. Jazz Pharmaceuticals manages this through its internal manufacturing capabilities or contracted third-party manufacturers.
• Finished Drug Product: The API is then formulated into the final dosage form, typically an oral solution, at Jazz Pharmaceuticals' manufacturing facilities or through contract manufacturing organizations (CMOs). The product is packaged and distributed under Jazz's direct control.

Generic Sodium Oxybate Manufacturing

The market for generic sodium oxybate has expanded following patent expirations and litigation. Several companies have entered the market or are in the process of doing so. Key players and potential manufacturers include:

• Amneal Pharmaceuticals: Has received FDA approval for its generic sodium oxybate oral solution.
• Mallinckrodt Pharmaceuticals: Has also been involved in the development and potential market entry of generic sodium oxybate.
• Other Generic Manufacturers: A range of other pharmaceutical companies are developing or have submitted Abbreviated New Drug Applications (ANDAs) for generic sodium oxybate. These include companies with broad generic portfolios capable of complex API synthesis and formulation.

What Are the Key Raw Materials and Intermediate Suppliers?

The synthesis of sodium oxybate requires specific chemical precursors and reagents. The supply chain for these materials is global and subject to quality control and regulatory compliance.

Primary Chemical Precursors

The synthesis of sodium oxybate typically starts from readily available chemical building blocks. A common route involves gamma-butyrolactone (GBL) as a key intermediate.

• Gamma-Butyrolactone (GBL): GBL is a widely used industrial solvent and precursor for various chemicals. Its production involves petrochemical feedstocks. Suppliers of GBL are typically large chemical manufacturers.
  • Note: GBL is also a controlled substance in some jurisdictions due to its illicit use as a recreational drug, which can impact its availability and regulatory scrutiny.
• Ammonia: Ammonia (NH3) is required for the amination step in the synthesis of sodium oxybate from GBL. Ammonia is a bulk chemical produced on a massive scale globally.

Reagents and Solvents

Beyond the primary precursors, the synthesis requires various reagents and solvents.

• Sodium Hydroxide (NaOH): Used in the final neutralization step to form the sodium salt of oxybate. This is a commodity chemical.
• Solvents: Common organic solvents such as methanol, ethanol, or isopropanol may be used during synthesis and purification steps. These are widely available from chemical suppliers.
• Catalysts: Specific catalysts may be employed depending on the chosen synthetic route to enhance reaction rates and yields.

Key Supplier Characteristics

Suppliers for these raw materials must meet stringent pharmaceutical quality standards, including Good Manufacturing Practices (GMP).

• API Manufacturers (for Generics): Companies developing generic sodium oxybate often rely on specialized API manufacturers. These manufacturers must have the capability to produce high-purity sodium oxybate consistently and comply with FDA and international regulatory requirements. Examples of potential API suppliers could include large-scale chemical synthesis companies in regions like India and China, which are prominent in global API production, as well as established US and European pharmaceutical ingredient manufacturers.
• Excipient Suppliers: While sodium oxybate is the API, the final oral solution formulation also contains excipients (e.g., water, flavorings, preservatives). These are typically sourced from specialized pharmaceutical excipient manufacturers who adhere to pharmacopeial standards (USP, EP).

How Is Sodium Oxybate Manufactured?

The manufacturing of sodium oxybate involves a chemical synthesis process followed by purification and formulation.

Chemical Synthesis of Sodium Oxybate

A common synthetic pathway for sodium oxybate (sodium 4-hydroxybutanoate) involves the following general steps:

1. Hydrolysis of Gamma-Butyrolactone (GBL): GBL is reacted with a strong base, such as sodium hydroxide, under controlled temperature and pressure. This opens the lactone ring to form the sodium salt of 4-hydroxybutanoic acid.
   • Reaction: GBL + NaOH → Sodium 4-hydroxybutanoate
2. Purification: The crude sodium 4-hydroxybutanoate is then subjected to purification steps to remove unreacted starting materials, by-products, and impurities. Techniques may include crystallization, filtration, and drying.
3. Quality Control: Rigorous analytical testing is performed at various stages to ensure the purity, potency, and identity of the API meet pharmaceutical specifications.

Formulation into Oral Solution

The purified sodium oxybate API is then formulated into the final drug product.

• Dissolution: The API is dissolved in purified water.
• Addition of Excipients: Flavoring agents (e.g., artificial flavors), preservatives (e.g., parabens), and other inactive ingredients are added to achieve the desired taste, stability, and shelf-life.
• Packaging: The final solution is filled into appropriate containers, typically amber glass bottles, to protect it from light, and then sealed.
• Quality Assurance: The finished product undergoes extensive quality control testing to confirm its concentration, pH, absence of microbial contamination, and compliance with all regulatory standards.

What Are the Regulatory and Legal Aspects Affecting Xyrem Supply?

The manufacture, distribution, and prescription of sodium oxybate are subject to strict regulatory controls due to its therapeutic use and potential for abuse.

Controlled Substance Status

Sodium oxybate is classified as a Schedule III controlled substance by the U.S. Drug Enforcement Administration (DEA). This classification imposes significant regulatory burdens on manufacturers, distributors, and healthcare providers.

• DEA Registration: All entities involved in handling sodium oxybate must be registered with the DEA.
• Quotas: The DEA sets annual aggregate production quotas for controlled substances, which can limit the total amount of sodium oxybate that can be manufactured in the U.S. each year.
• Record Keeping and Reporting: Strict records must be maintained for all transactions, and regular reports must be submitted to the DEA.
• Security: Facilities handling controlled substances must implement robust security measures to prevent diversion and theft.

Risk Evaluation and Mitigation Strategies (REMS)

Xyrem is subject to a specific REMS program approved by the FDA. This program is designed to mitigate the risks associated with its use, particularly the risk of respiratory depression, sedation, and abuse.

• Specialist Pharmacy Program: Xyrem is only available through a limited network of certified pharmacies that dispense directly to patients. These pharmacies must be registered with the REMS program.
• Patient and Prescriber Education: Both prescribers and patients must be educated about the risks and safe use of Xyrem.
• Prescription Tracking: Prescriptions are tracked to ensure compliance with the REMS program.
• Generic REMS: Generic versions of sodium oxybate must also comply with an approved REMS program, which may be comparable to or the same as the Xyrem REMS.

Patent Landscape and Litigation

The patent protection surrounding Xyrem has been a significant factor in market exclusivity and the eventual entry of generics.

• Key Patents: Jazz Pharmaceuticals held several patents covering the composition of matter, methods of use, and manufacturing processes for Xyrem.
• Patent Expirations and Challenges: As these patents approached expiration or were challenged, generic manufacturers began to file ANDAs.
• Litigation: Numerous patent litigations have occurred between Jazz Pharmaceuticals and generic companies seeking to market their versions of sodium oxybate. These litigations often determine the timeline for generic market entry. For instance, legal challenges by Jazz aimed to protect its market, while generic companies sought to invalidate patents or prove non-infringement.

FDA Approval Process

• New Drug Application (NDA): Jazz Pharmaceuticals obtained FDA approval for Xyrem via an NDA.
• Abbreviated New Drug Application (ANDA): Generic manufacturers must file ANDAs, demonstrating that their product is bioequivalent to the reference listed drug (Xyrem) and manufactured under GMP conditions.

What Are the Market Dynamics and Supply Chain Risks?

The supply chain for Xyrem is influenced by its therapeutic indications, regulatory environment, and the competitive landscape.

Therapeutic Indications

Xyrem is approved for two primary indications:

1. Narcolepsy: Specifically, to treat excessive daytime sleepiness (EDS) and cataplexy in patients with narcolepsy.
2. Idiopathic Hypersomnia (IH): Approved in 2021, broadening the patient population.

The demand for Xyrem is driven by the prevalence of these sleep disorders and physician prescribing patterns.

Supply Chain Vulnerabilities

Several factors can create vulnerabilities in the Xyrem supply chain:

• Controlled Substance Regulations: Strict DEA quotas and stringent handling requirements can limit production capacity and create bottlenecks. Any changes in DEA policy or enforcement can impact supply.
• REMS Compliance: Adherence to the REMS program requires significant logistical coordination between manufacturers, distributors, pharmacies, and healthcare providers. Failures in REMS compliance by any party can disrupt supply or lead to regulatory penalties.
• API Sourcing: Reliance on a limited number of API manufacturers for high-purity sodium oxybate can create single points of failure. Geopolitical instability, natural disasters, or quality issues at an API supplier could disrupt production.
• Manufacturing Complexity: The synthesis and formulation of a controlled substance require specialized expertise and facilities, limiting the number of potential manufacturers.
• Patent Litigation Outcomes: The resolution of patent disputes can significantly alter the competitive landscape and impact the supply of both branded and generic products.
• Distribution and Logistics: The specialized distribution channels required by the REMS program can be complex and susceptible to disruptions.

Competitive Landscape

The entry of generic sodium oxybate has increased competition and is expected to drive down prices.

• Jazz Pharmaceuticals: Continues to market Xyrem and has introduced its own lower-sodium formulation, Xywav, which is not a controlled substance, to address patient needs and potentially mitigate some of the regulatory burdens associated with sodium oxybate.
• Generic Manufacturers: Companies like Amneal Pharmaceuticals have launched generic versions, increasing market availability and offering lower-cost alternatives. This competition intensifies pressure on pricing and distribution strategies for all market participants.

Key Takeaways

• Jazz Pharmaceuticals is the sole manufacturer of brand-name Xyrem, while multiple generic manufacturers, including Amneal Pharmaceuticals, now produce sodium oxybate.
• The primary chemical precursor is gamma-butyrolactone (GBL), sourced from bulk chemical manufacturers.
• Sodium oxybate manufacturing involves a multi-step synthesis process followed by formulation into an oral solution, requiring cGMP compliance and specialized capabilities.
• The drug is a Schedule III controlled substance in the U.S., subject to DEA quotas, strict record-keeping, and security protocols.
• A REMS program mandates specialized pharmacy dispensing and patient/prescriber education, creating a closed distribution loop.
• Supply chain risks include regulatory stringency, reliance on specific API suppliers, and the complexities of controlled substance handling and REMS adherence.
• The market is characterized by increasing generic competition following patent expirations and litigation, with Jazz Pharmaceuticals also offering a non-controlled substance alternative, Xywav.

Frequently Asked Questions

What are the primary challenges in manufacturing sodium oxybate?

The primary manufacturing challenges include the intricate chemical synthesis of high-purity sodium oxybate, strict adherence to cGMP standards, and navigating the rigorous regulatory oversight associated with controlled substances and REMS programs. Ensuring a secure and compliant supply chain for precursors and intermediates is also critical.

How does the REMS program impact the supply chain for Xyrem and its generics?

The REMS program creates a highly controlled and limited distribution channel. Only certified pharmacies can dispense the drug, requiring direct-to-patient shipping and meticulous tracking. This closed system reduces diversion but adds complexity to logistics, inventory management, and patient onboarding, potentially impacting the speed and reach of supply.

Who are the major suppliers of gamma-butyrolactone (GBL) for pharmaceutical use?

Major suppliers of GBL are typically large chemical manufacturers with global production capabilities. Specific pharmaceutical-grade GBL suppliers are often vetted through rigorous quality assurance processes by drug manufacturers. Companies with significant chemical manufacturing operations in North America, Europe, and Asia are likely to be key sources.

What happens if a manufacturer fails to comply with DEA regulations or REMS requirements?

Failure to comply with DEA regulations for controlled substances can result in severe penalties, including significant fines, suspension or revocation of DEA registration, and criminal prosecution. Non-compliance with REMS requirements can lead to FDA enforcement actions, including product recalls, manufacturing shutdowns, and restrictions on marketing and distribution, ultimately disrupting supply.

How has the introduction of generic sodium oxybate affected the supply chain?

The introduction of generics has increased the number of entities involved in manufacturing and distributing sodium oxybate, potentially diversifying the supply base. However, it also intensifies competition, placing greater emphasis on efficient supply chain management, cost control, and regulatory compliance for all market participants. The controlled substance status and REMS requirements continue to constrain the overall market, regardless of the number of manufacturers.

---

Citations

[1] Jazz Pharmaceuticals. (n.d.). Xyrem Prescribing Information. Retrieved from [Pharmaceutical company website or FDA drug label database].

[2] U.S. Drug Enforcement Administration. (n.d.). Schedules of Controlled Substances. Retrieved from [DEA website].

[3] U.S. Food & Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (The Orange Book). Retrieved from [FDA website].

[4] Amneal Pharmaceuticals. (2023, October 16). Amneal Pharmaceuticals Announces Launch of Generic Sodium Oxybate Oral Solution. [Press Release]. Retrieved from [Company press release archive or financial news service].